JP MORGAN/CALL/MEDTRONIC/120/0.1/17.01.25 Stock

Warrant

DE000JL64E96

Market Closed - Börse Stuttgart 04:54:54 2024-06-28 EDT
0.018 EUR +5.88% Intraday chart for JP MORGAN/CALL/MEDTRONIC/120/0.1/17.01.25
Current month+50.00%
1 month+50.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-28 0.018 +5.88%
24-06-27 0.017 -10.53%
24-06-25 0.019 -9.52%
24-06-24 0.021 +23.53%
24-06-21 0.017 +6.25%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 04:54 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer J.P. Morgan
WKN JL64E9
ISINDE000JL64E96
Date issued 2023-06-16
Strike 120 $
Maturity 2025-01-17 (201 Days)
Parity 10 : 1
Emission price 0.23
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.28
Lowest since issue 0.01
Delta0.05x
Omega 11.05
Premium52.89x
Gearing229.66x
Moneyness 0.6559
Difference Strike 41.29 $
Difference Strike %+34.41%
Spread 0.03
Spread %63.83%
Theoretical value 0.0320
Implied Volatility 31.61 %
Total Loss Probability 97.06 %
Intrinsic value 0.000000
Present value 0.0320
Break even 120.34 €
Theta-0x
Vega0.01x
Rho0x

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
78.71 USD
Average target price
94.02 USD
Spread / Average Target
+19.46%
Consensus